Health Robotics' i.v.STATION ONCO Expands Global Footprint With Dominican Republic's Macrotech Farmaceutica

BOZEN, SUD-TIROL, Italy, June 1, 2011 /PRNewswire/ --

Health Robotics today announced a new exclusive distribution agreement for its world-leading i.v.STATION ONCO, i.v.SOFT, and i.v.STATION products with Dominican Republic-based leader Macrotech Farmaceutica. This new exclusive partnership represents Health Robotics' entry into its 20th new country over the past 2 years, persisting on its worldwide quest to pervasively provide safe and cost-effective Intravenous Admixture Compounding Automation to hospitals all over the world.

"On the heels of our recent market entrance in Latin America and the continued success in the USA and Canada with 10 new contracts this quarter, this new exclusive partnership with Macrotech represents the realization that our vision for networked and redundant Oncology compounding devices is rapidly taking hold all over the American continent", stated Gaspar DeViedma, Health Robotics' Executive Vice President.

i.v.STATION ONCO represents Health Robotics' second generation Cancer Therapy Compounding robot for syringes and I.V. Bags, introduced into the market well before our competitors can even install their first solutions at any global hospital, despite their 20+ year old fictional claims[1]. Amongst the technology innovations pioneered by i.v.STATION ONCO are its: ability to handle pre-attached lines to IV Bags; small footprint [at 15% to 25% of the size/weight of other marketed robots]; faster throughput [up to 40 doses per hour]; automated tamper-evident syringe capping; and RFID support.

"Our upcoming installation of i.v.STATION and i.v.SOFT Assist in 2011 followed by i.v.STATION ONCO in early 2012 represents a major milestone for our company and for the exponential improvement of safe and sterile compounding at our customer sites. We are all very excited at Macrtotech Farmaceutica to complete Health Robotics' technical training this Summer, and to conduct already scheduled safe-compounding strategy sessions with Gaspar DeViedma and our regional thought leaders throughout this Fall", stated Joaquin Toribio, Macrotech's General Manager.

About Macrotech Farmaceutica:

With locations in Santo Domingo, Miami, and other key sites throughout the Caribbean, Macrotech Farmaceutica is a pharmaceutical and biomedical engineering leader in the healthcare sector, focusing on the distribution and service for Intravenous solutions, medications, and sophisticated medical equipment, such as Baxter, Incol, Alpha, Stryker, and Globix. For additional information, please visit: http://www.mf.com.do/

About Health Robotics:

Health Robotics is the undisputed global leading supplier of life-critical intravenous medication robots, providing over 175 hospital installations in 6 continents with robotics technology and software automation solutions deployed utilizing virtual high-availability technology. Its world-leading solutions CytoCare(R) and i.v.STATION(R) ONCO [hazardous IVs], i.v.STATION(R) [non-hazardous IVs], i.v.SOFT(R) [workflow engine for manual compounding], MEDarchiver(R) [life-critical clinical information system], and TPNstation(TM) [totally-automated parenteral nutrition] have and will greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' solutions help hospitals eliminate life-threatening drug and diluent exchange errors, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com

    
    For additional information, please contact:
    Claudia Flaim, Marketing Coordinator
    flaim@health-robotics.com
    Phone: +39-0471-200-372

    ---------------------------------

    [1]Am J Hosp Pharm 46(11): 2286-93 1989